Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.

First Received: June 6, 2002 Last Updated: February 6, 2009 History of Changes

Sponsor:	Fox Chase Cancer Center
Collaborator:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00039507

Purpose

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.

Condition	Intervention	Phase
Lung Cancer	Procedure: conventional surgery Procedure: radiofrequency ablation	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer Surgery

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:

June 2002

Detailed Description:

OBJECTIVES:

Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer.
Determine the treatment-related toxicity in patients treated with this therapy.
Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients.

OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection.

PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of malignant non-small cell lung cancer (NSCLC)
- Intraoperative needle biopsy confirmation allowed
Resectable disease (stage I or II)
All tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection
Medically fit to undergo lung resection

PATIENT CHARACTERISTICS:

Age:

Over 18

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

No prior or concurrent biologic therapy

Chemotherapy:

No prior or concurrent chemotherapy

Endocrine therapy:

No prior or concurrent endocrine therapy

Radiotherapy:

No prior or concurrent radiotherapy

Surgery:

See Disease Characteristics

Other:

No other prior therapy for NSCLC

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00039507

Locations

United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111

Sponsors and Collaborators

Fox Chase Cancer Center

National Cancer Institute (NCI)

Investigators

Study Chair:

Walter J. Scott, MD, FACS

Fox Chase Cancer Center

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CDR0000069389, FCCC-02007, NCI-G02-2079
Study First Received:	June 6, 2002
Last Updated:	February 6, 2009
ClinicalTrials.gov Identifier:	NCT00039507 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

stage I non-small cell lung cancer
stage II non-small cell lung cancer

Additional relevant MeSH terms:

Thoracic Neoplasms
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type
Respiratory Tract Diseases

Lung Neoplasms
Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

ClinicalTrials.gov processed this record on November 09, 2009